European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Novo traded down more than 20% Friday morning, its biggest loss since 2002. The CagriSema news boosted competitors, such as ...

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...